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Breast cancer is an estrogen-driven disease. Consequently, hor-
mone replacement therapy correlates with disease incidence.
However, increasing male breast cancer rates over the past three
decades implicate additional sources of estrogenic exposure in-
cluding wide spread estrogen-mimicking chemicals or xenoes-
trogens (XEs), such as bisphenol-A (BPA). By exposing
renewable, human, high-risk donor breast epithelial cells
(HRBECs) to BPA at concentrations that are detectable in hu-
man blood, placenta and milk, we previously identiﬁed gene
expression proﬁle changes associated with activation of mam-
malian target of rapamycin (mTOR) pathway genesets likely to
trigger prosurvival changes in human breast cells. We now pro-
vide functional validation of mTOR activation using pairwise
comparisons of 16 independent HRBEC samples with and with-
out BPA exposure. We demonstrate induction of key genes and
proteins in the PI3K-mTOR pathway—AKT1, RPS6 and 4EBP1
and a concurrent reduction in the tumor suppressor, phospha-
tase and tensin homolog gene protein. Altered regulation of
mTOR pathway proteins in BPA-treated HRBECs led to
marked resistance to rapamycin, the deﬁning mTOR inhibitor.
Moreover, HRBECs pretreated with BPA, or the XE, methyl-
paraben (MP), surmounted antiestrogenic effects of tamoxifen
showing dose-dependent apoptosis evasion and induction of cell
cycling. Overall, XEs, when tested in benign breast cells from
multiple human subjects, consistently initiated speciﬁc func-
tional changes of the kind that are attributed to malignant onset
in breast tissue. Our observations demonstrate the feasibility of
studying renewable human samples as surrogates and reinforce
the concern that BPA and MP, at low concentrations detected in
humans, can have adverse health consequences.
Introduction
Bisphenol-A (BPA) and methylparaben (MP) are xenoestrogens (XEs),
i.e. non-steroidal chemicals that act like estrogens (1,2). BPA, a com-
monly used plasticizer, is so widely dispersed in the environment that 9
of 10 North Americans test positive in random urine samples (3,4). BPA
has a short physiologic half-life, but due to continuous environmental
exposure, BPA is routinely detected in human blood (5), placenta, cord
(fetal) blood (6), fetal liver (7) and breast milk (8). BPA binds to estro-
gen receptors (ER) a and b (9,10) and reverses antiestrogen- (11) and
chemotherapy-induced cytotoxicity in cancer cell lines (12). BPA in-
duces upregulation of AKT (v-Akt murine thymoma viral oncogene
homolog 1) in association with increased proliferation and decreased
apoptosis of epithelial cells in breast tissue of lactationally exposed rats
(13), as well as histological changes associated with mouse mammary
carcinogenesis after in utero exposure (14). These effects are speciﬁc to
breasttissuessinceBPAtreatmentofadipocytes(15)andleukemiacells
(16) reduces phosphorylation of the serine/threonine protein kinase
AKT and promotes terminal differentiation and cell death. MP, a com-
mon preservative in medicines, toiletries and skin care products (2), is
detectedinhuman breast tumors(2,17) and induces estrogenicsignaling
in the MCF7 breast cancer cell line (18,19). Because breast cancer
incidence is proportional to estrogen exposure (20,21), there is concern
thatsuchestrogen mimics havecontributedtoincreasedbreastcancerin
both women and men over the last three decades (22,23).
To test the validity of insights acquired from animal and cancer cell
line models, we developed assays based on renewable, early passage,
non-malignant, high-risk donor breast epithelial cell (HRBEC) cultures
derived from fresh human samples. In global gene expression analysis,
HRBECs exposed to a low concentration of BPA exhibited geneset alt-
erations that predicted activation of the mammalian target of rapamycin
(mTOR) pathway (24) thereby implicating XE-induced effects in desta-
bilizing a central function in normal cells. For example, downregulation
of the mTOR pathway often occurs in a nutrient-poor microenvironment,
thereby, limiting cell proliferation and allowing cell death through apo-
ptosis and autophagy (25). However, when activated by hormones and/or
abundant nutrition, or when co-opted in cancer development, mTOR
signaling initiates protein synthesis, cell proliferation and evasion of
apoptosis (25,26). In an independentset ofHRBECsamplesfrom similar
high-risk individuals, we now demonstrate activation of key mTOR
pathway proteins induced by XE exposure and downstream functional
consequences. The use of HRBECs sidesteps issues of interspecies var-
iation by testing cells from at-risk humans and bypasses issues of dose,
route of delivery and metabolism by examining the effects of XE con-
centrations found in human tissues and body ﬂuids (27,28). Because live
HRBECs are drawn directly from the population of interest, i.e. the
heterogeneous population of women at high risk of breast cancer occur-
rence, they serve well as surrogates for the effects of XEs on this pop-
ulation. The functional changes induced by BPA and MP closely parallel
known outcomes of mTOR pathway activation (26) and tumor behavior
(29) and reveal an underlying mechanistic basis for restricted effective-
ness of breast cancer treatment and prevention strategies.
Materials and methods
Random periareolar ﬁne needle aspirate collection and cytopathology
With Institutional Review Board-approved written informed consent, non-
malignant cells were obtained by random periareolar ﬁne needle aspiration from
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We use the acronym HRBEC to represent ‘high-risk donor breast epithelial cells’.
HRBEC donors were recruited based on personal or family history of breast
cancer, atypical or neoplastic histopathology on biopsy and/or high mammo-
graphic density (30). Specimen size was  0.2 ml per volunteer including extra-
neous fat, blood and debris. Random periareolar ﬁne needle aspirate (RPFNA) cell
suspension was divided into aliquots for cytopathology and cell culture.
The cytology aliquot was collected in CytolytTM, centrifuged at 600 r.p.m. for
10 min, transferred under vacuum to 20 mm circles on ThinPrepTM microscope
slides using the ThinPrepTM 2000 processor (Cytec Corp., Boxborough, MA),
ﬁxed in 95% alcohol for 10 min and processed through an automated staining
and mounting set up (Sakura Finetek USA, Torrance, CA). The entire 20 mm
circle was evaluated by a board-certiﬁed cytopathologist (I.J.) for cytological
atypia, and the number of epithelial and stromal cell clusters was counted.
Aliquots for cell culture were transferred into DME-F12 serum-free growth
medium and transported on ice to the laboratory for delivery within 2 h.
Propagation and chemical exposure of HRBECs
Epithelial cells within RPFNA samples were plated and propagated in MCDB
170 medium supplemented with2% fetal bovineserum asdescribed previously
(24). Twenty-three independent samples were expanded invitro and used in the
assays described below. The breast cancer cell lines—T47D, MCF7 and
SKBR3—were used as controls and adapted to the same growth medium as
HRBEC cultures prior to each assay. After 2–3 weeks of expansion, HRBECs
were harvested for a variety of functional response tests.
To determine three-dimensional growth patterns, HRBECs were plated as
single cell suspensions in a semisolid growth substrate comprised 3% Matrigel
(BD Biosciences, San Jose, CA) and propagated for 10 days. Colonies ﬁxed
with 1:1 methanol:acetone were incubated with anti-alpha-6 integrin (BD
Pharmingen, San Diego, CA) followed by ﬂuorescence-tagged secondary an-
tibody and propidium iodide (PI) nuclear counterstain. Immunostained colo-
nies were visualized by confocal microscopy.
For XE exposure, cells were plated at a density of 100 000 cells per well in
six-well plates and exposed to continuous 7 day treatments with 17b-estradiol
(5 nM), 100 pM to 100 nM BPA or 10 nM to 1 lM MP in phenol red-free
medium supplemented with 0.2% charcoal-stripped fetal bovine serum. Where
indicated, cells were exposed to 10 lM 4-hydroxy tamoxifen (OHT) or to 1, 10
or 100 nM rapamycin for 24 h prior to functional analysis. All chemicals were
purchased from Sigma–Aldrich (St. Louis, MO).
Protein detection by western blot analysis
Cells were lysed in denaturing lysis buffer in the presence of protease and
phosphatase inhibitors and sonicated to disrupt cellular and nuclear mem-
branes. Equal amounts of cell lysates were loaded onto 4–15% gradient gels
for sodium dodecyl sulfate–polyacrylamide gel electrophoresis analysis, trans-
ferred to PVDF membranes and used for immunodetection with primary anti-
bodies to ERa (Santa Cruz Biotechnology, Santa Cruz, CA), ERb (Genetex,
San Antonio, TX), phosphatase and tensin homolog gene (PTEN) (Cell Sig-
naling Technology, Beverly, MA), PTEN phosphorylated at S380/T382/T383
(Santa Cruz Biotechnology), AKT1 (Santa Cruz Biotechnology), AKT1 phos-
phorylated at S473 (Santa Cruz Biotechnology), RPS6 (Genetex), RPS6 phos-
phorylated at S235/S236 (Genetex) and 4EBP1 (Santa Cruz Biotechnology).
Actin, served as a loading control.
Real time quantitative polymerase chain reaction analysis
Total RNA was isolated using the RNeasy Kit (Qiagen, Valencia, CA) from
untreated control and XE-treated cells. RNA concentration was determined by
NanoDrop 2000 (Thermo Scientiﬁc, Lafayette, CO). Complementary DNA
was synthesized and analyzed as before (31) by an Applied Biosystems
5700 Sequence Detection System (Applied Biosystems, Foster City, CA).
The Ct values of test genes were normalized to the expression of the house-
keeping genes, ACTB and GAPDH, within each HRBEC sample to represent
log base 2-fold increase or decrease in test gene expression over no XE con-
trols. Primer sequences for test genes are listed in supplementary Table S1
(available at Carcinogenesis Online).
Analysis of apoptotic and S-phase cell fractions
For quantitation of apoptotic cells, cultures were harvested and stained with An-
nexin V-FITC and PI (BD Biosciences) according to the manufacturer’s protocol.
Cells diluted in binding buffer were analyzed by FACScan (BD Biosciences) and
quantiﬁed by CellQuest software (BD Biosciences). Annexin-V-positive cells
were measured as ‘early’ (PI-negative) and ‘late’ (PI-positive) apoptotic cell frac-
tions. Each measurement was performed in multiple replicates.
For S-phase quantitation, cells were pulse labeled with 10 lMb r o m o d e o x -
yuridine for 1 h, stained with anti-bromodeoxyuridine (Santa Cruz Biotechnol-
ogy), FITC-conjugated secondary antibody (Invitrogen, Carlsbad, CA),
counterstained with PI and analyzed by FACScan.
Quantitation of endogenous reactive oxygen species
Endogenous cellular reactive oxygen species (ROS) accrual was determined
using live cell cultures loaded with the ﬂuorogenic dye, carboxy-H2DCFDA
(5-(and-6)-carboxy-2#7#-dichlorodihydroﬂuorescein diacetate), also known as
C-400 (Invitrogen) in phenol red-free medium for 1 h followed by 30 min
incubation in regular growth medium. After dye removal, cells were counter-
stained with PI, and intracellular oxidation of C-400 was measured by FACS-
can with the FL1 ﬁlter. Experiments were done in triplicate and 10 000 cells
were acquired for each sample. ROS activity was expressed as mean ﬂuores-
cence intensity (MFI) of the C400 dye. MFI of PI-negative (non-necrotic) cells
was corrected for autoﬂuorescence of unlabeled cells.
Results
Live HRBEC cultures display non-malignant breast epithelial
attributes
In this study, HRBECs were derived from the unafﬂicted contralateral
breast tissue of 23 individual volunteers (mean age—58, range 40–81
years). Sixteen women had a personal history of breast cancer, 4
displayed high-risk histopathology, 20 had mammographically dense
breasts and 19 had family history of breast cancer (supplementary
Table S2 is available at Carcinogenesis Online). Routine cytology
of the samples prior to cell culture showed multiple epithelial clusters
(range 4 to .200). No atypia was seen (Figure 1A). RPFNA samples
yielded short-term epithelial cultures with variable degrees of growth
potential. Generally, the initial cell seeding produced robust growth
within 2–3 weeks, enabling culture expansion for up to three passages
and providing morphologically homogeneous populations of 106–107
epithelial cells. Due to the low serum concentration of the growth
medium, stromal ﬁbroblast expansion did not occur (Figure 1B).
There were no selection criteria for RPFNA sampling except that
the volunteer present a clinically deﬁned increased risk of breast
cancer. HRBECs were used as they grew out in sufﬁcient numbers
for one or more assays. Identiﬁcation of the samples employed is
included in the relevant data ﬁgures. Our overall cell culture experi-
ence with .130 RPFNA samples thus far yielded three spontaneously
immortalized (IMM) HRBEC cell lines, designated as IMM-PA024,
IMM-PA025 and IMM-PA115, currently at passages 24–26.
Non-malignant epithelial characteristics of HRBEC cultures in-
cluded:
a. Polarized growth in Matrigel—unlike breast cancer cell lines
propagated in a three-dimensional matrix (which develop apolar col-
onies with random orientation of nuclei and the basement membrane
protein, alpha-6 integrin), HRBEC colonies were distinctive. Polar-
ized colonies, which displayed an acinar pattern of nuclear orientation
and characteristic basal immunolocalization of alpha-6 integrin, were
observed in all HRBEC cases tested (Figure 1C).
b. ER expression—distinct from ER-positive breast cancer cell
lines, represented by T47D and MCF7, which express abundant
ERa, and the ER-negative cancer cell line, SKBR3 in which ERa is
undetectable, HRBEC lines (IMM-PA024, IMM-PA025 and IMM-
PA115) displayed a low to moderate range of receptor protein (Figure
1D). On the other hand, levels of ERb were relatively similar between
HRBEC and cancer cell lines. Protein levels of both ER isoforms in
six independent early passage HRBEC cultures (PA134, PA135,
PA136, PA138, PA139 and PA140) were closely similar to those of
spontaneously immortalized counterparts. We conclude that unlike
many cancer cell lines, HRBECs represent an ERa-low/moderate
status. Levels of both ERa and ERb proteins are consistent with the
characteristics of non-malignant human breast cells (32,33).
Early passage HRBEC cultures (passage 2 or 3) of 23 independent
cases were used to generate subsets of data described below. HRBECs
from 16 cases were used for pairwise analysis in functional assays
(supplementary Table S2 is available at Carcinogenesis Online). Like
normal human epithelial cells, HRBECs display a ﬁnite life and sen-
esce after three passages, providing a limited amount of starting ex-
perimental material. For this reason, it is usually possible to pursue
only one or twowhole cell-based assays from a single sample, such as
determination of apoptotic fraction, ROS estimation or assays based
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reaction (QPCR) or by microarrays (reported by us previously). Sim-
ilarly, early passage HRBEC-derived protein lysates are often insuf-
ﬁcient for quantitative sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and western blot analysis. Therefore, we have in-
cluded immortalized-HRBEC lines in protein quantitation studies.
BPA exposure modulates the signal transduction cascade of the
PI3K–mTOR pathway within non-malignant breast epithelial cells
By QPCR analysis of the subset of critical mTOR pathway genes,
early passage HRBECs derived from six individuals demonstrated
identiﬁable shifts in expression associated with BPA exposure (Figure
2A). Considerable inter-subject variability in relative transcript levels
Fig. 1. RPFNA-derived HRBEC cultures display characteristic non-malignant epithelial phenotypes. (A) Micrographs of cell clusters present in independent
representativeRPFNAsamples.(B) Early passagepureepithelialculturesderivedfrom clusterssimilarto thoseshown in A(Brightﬁeld,  4 objective). (C) Three-
dimensional growth pattern of colonies derived from early passage HRBEC cultures in Matrigel. Basal immunolocalization of alpha-6 integrin (blue) and acinar
orientation of nuclei (red) in 10 day-old colonies. (D) Relative ERa and ERb protein levels in breast cancer cell lines (T47D, SKBR3 and MCF7), spontaneously
immortalized HRBEC lines (IMM-PA024, IMM-PA025 and IMM-PA115) and early passage HRBECs (PA134, PA135, PA136, PA138, PA139 and PA140)
quantitated by western blotting. Numerical values of each protein band representing ERa or ERb obtained by densitometric scanning were normalized to actin
levels in the lysate and plotted. Note low to moderate ERa levels in HRBECs relative to T47D and MCF7, but higher than the SKBR3 cell line, HRBECs display
a distinctive ER proﬁle unlike conventional ER-positive or ER-negative breast cancer cell lines.
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1726Fig. 2. BPA exposure modulates expression of mTOR pathway components and induces functional changes in breast epithelial cells. (A) QPCR measurements of
relative transcript levels of mTOR pathway genes in early passage HRBEC cultures (PA024, PA025, PA072, PA075, PA081 and PA112) normalized to
housekeeping genes. Data represent exposure to a low dose range of BPA or to a luteal serum estradiol (E2) level. Plotted values represent fold change for each
gene in treated samples, relative to the corresponding untreated control sample. Each data point is an average of triplicate QPCRs. (B) BPA-induced alterations in
mTOR pathway proteins in early passage (PA138 and PA140), immortalized HRBECs (IMM-PA024, IMM-PA025 and IMM-115) and breast cancer cells (T47D).
Pretreatment with BPA reduces steady-state PTEN protein levels and promotes functional inactivation by increased phosphorylation (indicated by ‘P’) at sites
S380/T382/T383 compared with untreated controls. Increased expression of total and phosphorylated AKT1 (at S473), RPS6 (at S235/236) and 4EBP1 (at multiple
sites) is detectable in both non-malignant and malignantbreast cells. Asterisks indicate shift in the molecular weight of phosphorylated 4EBP1.(C) Effects of BPA
pretreatment in the induction of resistance to the mTOR inhibitor, rapamycin. Data plotted to represent Annexin V-positive apoptotic populations within breast
cancer cell lines (T47D, SKBR3—left panel) and HRBEC lines (IMM-PA024, IMM-PA025, IMM-PA115—right panel). Each bar represents the mean and
standard deviation of triplicate values. Increased apoptotic ratios were observed with increasing doses of rapamycin in all cultures without BPA pretreatment.
Values demonstrating the effect of BPA in reducing rapamycin-induced apoptosis were statistically signiﬁcant in all cell lines (P . 0.001).
XE-induced hallmarks of cancer
1727was associated with the cellular BPA response, due to which dose–
response relationships were not detectable in this small sample size.
However, normalized to housekeeping genes, a consistent decline was
noted in transcript levels of the suppressor genes, PTEN (P 5 0.02,
two-tailed t-test against theoretical ratio 5 1.0), TSC1 and TSC2 (P 5
0.03). Conversely, downstream activators of the mTOR pathway,
e1F4B and e1F4E, were upregulated in the presence of BPA (P 5
0.003). Expression of PIK3R1, another mTOR activator, was ele-
vated (P 5 0.02), transcript levels of RPS6, a downstream effector of
mTOR that is activated by phosphorylation, were unexpectedly
lower (P 5 0.03) and there was a trend (P 5 0.07) toward increased
mTOR transcripts.
Conﬁrmation of the observed transcriptional alterations was sub-
sequently pursued at the protein level comparing two early passage
HRBEC cultures, three immortalized HRBEC lines and an ERa-pos-
itive breast cancer cell line, T47D (Figure 2B). As predicted by gene
transcript quantitation, BPA exposure led to the following: a signiﬁ-
cant reduction in total PTEN protein levels; an increase in the inactive
phosphorylated form of PTEN (PTENSer380/2/3) and increased total
and phosphorylated (activated) forms of the mTOR activating kinase,
AKT1 and two major downstream targets of mTOR: RPS6 and of
4EBP1 (at multiple sites, as shown by the increased molecular weight
of the phosphorylated protein). Unlike RPS6 transcript data, pRSP6
levels were representative of mTOR pathway activation. Increased
phosphorylation observed for upregulated proteins is strongly indic-
ative of increased mTOR activity and consistent with the ﬁnding of
higher mTOR transcript levels.
XE exposure induces evasion of apoptotic cell death in HRBEC
cultures
In order to establish additional functional association with mTOR
pathway regulation, we asked whether BPA pretreatment altered the
sensitivity of IMM-HRBEC lines to the antitumor drug—rapamycin,
a potent mTOR inhibitor. A signiﬁcant reduction in rapamycin-in-
duced apoptotic cell death was observed after BPA exposure of im-
mortalized HRBECs and in ERa-positive as well as ERa-negative
breast cancer cells (Figure 2C). This effect of BPA in circumventing
cell death was most prominent at 100 nM rapamycin, a concentration
at which the apoptotic ratio of drug-treated versus untreated control
was .2-fold in the absence of prior BPA exposure.
To further assess a role for XEs in the evasion of apoptotic cell
death, the antiestrogenic OHTwas used to initiate cell death. Early
passage HRBECs from eight subjects were compared with IMM-
HRBEC lines and with breast cancer cell lines. Percent apoptotic
cells were estimated in untreated control cells, those pretreated
with 100 nM BPA or 1 lM MP prior to a 24 h OHT exposure or
those exposed to OHTalone. Although the percentage of apoptotic
cells was doubled in the presence of OHT alone in all cell cultures
tested, the effect of OHT was almost undetectable in XE-treated
cultures (Figure 3A). Representative FACS data are illustrated in
Figure 3B.
In separate experiments, early passage HRBECs were evaluated
for the potential to evade apoptosis after exposure to a wide range of
BPA and MP concentrations (Figure 3C as averaged data and sup-
plementary Figure S1 is available at Carcinogenesis Online for each
sample). Maximum protection from apoptotic death was conferred
by exposure to 100 nM BPA (58.39 ± 6.8%). An appreciable degree
of apoptosis reduction was also observed at 10- to 100-fold lower
BPAdoses: 52.84±6.8%at 10 nM,41.24 ±10.4%at 1 nMand 19.93
± 7.9% at 100 pM (Figure 3C, left panel). A signiﬁcant dose–re-
sponse was observed when log BPA concentration was regressed on
l o gp e r c e n tr e d u c t i o ni na p o p t o s i s( P 5 0.002, two-sided test for
logistic regression). MP exposure of HRBECs also dramatically re-
duced the fraction of OHT-induced apoptotic cells at all three doses
tested: 57.82 ± 6.77% at 1 lM (Figure 4A), 55.93 ± 10.54% at 100
nM and 28.14 ± 11.3% at 10 nM (Figure 3C, right panel). Similar to
the BPA dose response, MP-induced changes in HRBECs were also
concentration dependent (P 5 0.001).
XE exposure modulates cellular oxidative stress in HRBEC cultures
To determine whether functional changes in apoptosis evasion and
cell survival werewith a reﬂection of oxidative stress reduction, levels
of endogenous ROS were quantiﬁed in early passage HRBECs, IMM-
HRBEC lines and breast cancer cell lines. The MFI of C400-stained
cells was used as an indicator of ROS. OHT treatment was used as
a positive control for ROS induction. Both BPA and MP induced
a detectable decline in endogenously accumulated ROS in all cell
cultures during the 7 day exposure period (Figure 4A). Representative
FACS data are illustrated in Figure 4B.
In further experiments, neutralization of ROS was measured in re-
sponse to increasing log concentrations of BPA and MP exclusively in
early passage HRBECs (Figure 4C as averaged data and supplemen-
tary Figure S2 is available at Carcinogenesis Online for each sample).
The average reduction in ROS by BPA treatment was 26% (95% CI
24–28%; P , 0.001, two-sided t-test against theoretical ratio 5 1.0,
Figure 4C, left panel). Similarly, the average ROS reduction by MP
treatment was 38% (95% CI 24–48%; P , 0.02, Figure 4C, right
panel). A dose–response relationship was not observed for this end
point.
XE-mediated cell cycle changes surmount drug-induced HRBEC
growth inhibition
To determine whether resistance to OHT-induced apoptosis in BPA or
MP-pretreated cells was accompanied by the maintenance of prolifera-
tive potential, we measured the efﬁciency of bromodeoxyuridine incor-
poration during the S-phase of the cell cycle in IMM-HRBEC lines.
Prior exposure to a dose range of either BPA or MP resulted in a dra-
matic, concentration-dependent complete to partial evasion from the
G1-phase arrest induced by 10 lM OHT and a concurrent increase in
the S-phase fraction (Figure 5A and B). In contrast, the growth inhibi-
tory effects of OHT were not reversed by a simulated physiological
scenario of a combination of luteal phase serum levels of 17b-estradiol
and progesterone in the absence of BPA (data not shown). As with
apoptosis evasion, maintenance of S-phase in OHT-treated cells was
signiﬁcantly correlated with increasing concentrations of BPA and
MP (P , 0.001 for BPA; P , 0.001 for MP, two-sided test for mixed
effects linear regression).
Discussion
We demonstrate that BPA activates the mTOR pathway in non-
malignant HRBECs. Both transcript and protein quantitation analyses
reﬂected changes in the most importantrepresentativeelementsof this
signaling pathway. In live cells, BPA suppresses apoptosis, enhances
S-phase and decreases ROS levels, a well-known prelude to apoptosis
evasion. Live cells respond in a similar manner to the XE, MP, sug-
gesting that mTOR activation might be a general effect of XEs. These
functional assays servetotest and conﬁrm the consequences of mTOR
activation predicted by global expression proﬁling of a previous in-
dependent set of BPA-exposed HRBECs (24).
Chemicals tested here are so common in bodily ﬂuids (3–8) as to
make unexposed control subjects functionally, if not literally, unavail-
able. We provide a pragmatic approach to overcome this problem by
using live, renewable breast epithelial cell samples from high-risk do-
nors (HRBECs) propagated in vitro with and without the chemicals of
interest for pairwise comparisons of known end points of mTOR acti-
vation. HRBECs are samples from women who, based on extensive
epidemiology, are identiﬁable as predisposed to malignant progression,
even before overt cytopathological alterations are present. The oppor-
tunitytodemonstrateaconcordantsetofmultipleend points portraying
the status of the mTOR metabolic pathway—despite small sample
size—underscores the suitability of this source of target human cells
for recapitulating early functional changes induced by carcinogen ex-
posure. There is, and always will be, a gap between human biology
invivoanditsrepresentationbysurrogateinvitromodels,butunlikethe
limited genotypic variation represented by common immortalized cell
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1728Fig. 3. XEexposurepromotesapoptosisevasionin HRBECcultures.(A) PotentialforXE-inducedapoptosisevasionmeasuredaspercentreductionin AnnexinV-
positive cells by FACS analysis. Breast cancer cell lines (T47D and SKBR3), HRBEC cell lines (IMM-PA024, IMM-PA025 and IMM-PA115) and early passage
HRBEC (PA094, PA099, PA103, PA106, PA107 and PA130) exposed to BPA or MP were treated with OHT for 24 h prior to Annexin V staining and compared
with untreated controls. All experiments were performed in triplicate. Plots illustrate average values and the standard deviation for each culture group under
conditionsofnotreatment,XEexposurefollowedbyOHTorOHTtreatmentalone.Valuesdemonstratingthe effectofXEs inreducingOHT-inducedapoptosisare
statistically signiﬁcant in all cases (P , 0.002). (B) FACS proﬁles of representative samples. M1 fraction—autoﬂuorescence; M2—Annexin V-positive cells
(which increase with OHT treatment). (C) Dose–response measurements (shown as decreasing XE concentrations from left to right) in early passage HRBECs. In
XE-induced hallmarks of cancer
1729lines, HRBECs more closely reﬂect the diversity of genetics, exoge-
nous hormone use, life events such as pregnancy, etc. of women en-
counteredinclinicalpractice.OurdemonstrationthatHRBECsfromall
subjects displayed prosurvival changes after XE exposure does not
claim that all exposed persons will develop cancer, only that such
exposure can cause changes that may facilitate malignant progression.
Fig. 4. XE exposure alters oxidative stress levels in breast epithelial cells. (A) Comparative analysis of intracellular ROS levels measured and quantiﬁed by FACS
analysis of C400-stained cancer cell lines (T47D and SKBR3), HRBEC lines (IMM-PA024, IMM-PA025 and IMM-PA115) and early passage HRBEC cultures
(PA094, PA099, PA103, PA106, PA107 and PA130) exposed to BPA or MP. A post-XE 24 h treatment with tamoxifen (OHT) was used to induce ROS. All
experiments were performed in triplicate. Averaged data representing the MFI of C400 are plotted, and standard deviations are shown. Values demonstrating the
effect of XEs in reducing OHT-induced ROS are statistically signiﬁcant in all cases (P , 0.0001). (B) FACS proﬁles of representative samples. The area under
each curve reﬂects C400-positive cells. Note the right shift of the C400 peak in OHT-treated samples (indicating higher MFI) when compared with untreated
control populations (top two panels) and the mild reduction of MFI in cells exposed to XEs (bottom two panels). (C) ROS levels measured as C400 MFI in early
passage HRBECs exposed to various concentrations of BPA or MP. Results are expressed as percent reduction from baseline MFI of no XE controls. Each data
point represents an average of six independent HRBEC samples (shown individually in supplementary Figure S2, available at Carcinogenesis Online). Error bars
display the variation between cases.
all cases, the protection from OHT-induced apoptosis (apoptotic evasion) was calculated as a fraction of the apoptotic response in the absence of XEs (set to 1).
Each data point represents an average of eight independent HRBEC samples (shown individually in supplementary Figure S1 is available at Carcinogenesis
Online). Error bars display the variation between cases (triplicate values for each case). Note a striking dose–response effect for both XEs, despite variability
between samples in the protection from OHT-induced apoptosis.
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targets of interest are essential for carcinogenicity testing. For exam-
ple, to evaluate the role of XEs in the initiation of breast cancer,
HRBECs are particularly well suited because they consistently ex-
press low/moderate levels of both ERa and ERb. Earlier studies that
did not distinguish ER isoforms (as continues in current clinical prac-
tice where primarily ERa is measured) typically reported low ER
positivity in normal or benign breast tissue (32–34), suggesting that
this phenotype is sufﬁcient for agonistic activity of natural and syn-
thetic estrogens, as well as for antagonistic effects of tamoxifen in
reducing breast cancer incidence in randomized trials (35,36), even in
patients harboring ER-negative atypia (37). Thus, high ERa levels are
not a prerequisite for XEs to exert their biological effects either clin-
ically or invitro. Similarly, reversal of tamoxifen toxicity by exposure
to the common XEs, BPA and MP, implies that the ER proﬁle of
HRBECs is also sufﬁcient for the induction of cancer-associated phe-
notypes by estrogenic chemicals.
Against the backdrop of non-malignant ER levels simulated by
HRBECs, BPA-induced transcriptional and protein alterations char-
acteristic of breast cancer were discernible. For example, activation
by phosphorylation of AKT is a key regulatory step in subsequent
mTOR activation and induction of cell growth (25). During in vitro
morphogenesis and differentiation of acini from non-malignant cells
in Matrigel, pAKT localizes to peripheral cells, away from the central
apoptotic region (38). Moreover, constitutive pAKT expression pre-
vents lactogenic differentiation (39). Expectedly therefore, pAKT is
increased during RAS-induced carcinogenesis of MCF10 xenografts
(40) and pAKT is necessary for carcinogenic progression in this
model since blocking pAKT results in apoptotic cell death (40). Clin-
ically, a similar progression is observed whereby pAKT is signiﬁ-
cantly higher in malignant than benign breast tissue (41) and pAKT
levels in cancer correlate directly with poor prognosis (42,43). Con-
versely, in vitro PTEN inactivation by phosphorylation and reduction
in protein levels parallel Cowden’s syndrome where PTEN loss of
function is associated with an increase in breast and other cancers
(44,45). Downstream, mTOR acts by phosphorylating (activating)
4EBP1 and RPS6 (indirectly through p70S6K activation). Both
p4EBP1 and its target eIF4E increase during experimental carcino-
genesis (40); p4EBP1 is higher in cancer than in benign biopsies (41)
and associated with higher tumor grade (46); and consequently,
p4EBP1 correlates directly with tumor recurrence in women (46).
In vitro, pRPS6 is downregulated by exposure to rapamycin (a de-
ﬁning mTOR inhibitor) in 12/12 cell lines (46,47). In one series,
pRPS6 did not correlate with prognosis, but it was upregulated in
the majority (77%) of breast cancers (46). mTOR activation by
BPA exposure is further deﬁned by inhibition of rapamycin-induced
Fig. 5. XE exposure compromises tamoxifen-mediatedcell cycle arrest in breast epithelialcells—(A) Cell cycledata derived from bromodeoxyuridine labelingof
HRBEC lines (IMM-PA024, IMM-PA025 and IMM-PA115). Representative pie charts illustrate percent cells in different phases of the cell cycle (red—S-phase,
yellow—G2, green—G1 and blue—sub G1). Note reversal of OHT-induced G1 arrest and subsequent S-phase decline in XE-pretreated cells. IMM-PA115 is
relatively insensitiveto the MP concentration shown compared with the othertwo HRBEClines. (B) Graphicalsummaryof S-phasereduction in OHT-treatedcells
and maintenance of S-phase by BPA (left panel) and MP (right panel) pretreatment in response to decreasing concentrations (from left to right). Plots represent an
average of the combined bromodeoxyuridine-positive populations and standard deviations around the mean within independent HRBEC lines exposed to either
BPA or MP (IMM-PA024, IMM-PA025 and IMM-PA115), shown individually in supplementary Figure S3 (available at Carcinogenesis Online).
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1731apoptosis (48), which is the converse of the therapeutic beneﬁt of
rapamycin analogs achieved through suppression of the mTOR path-
way (49,50). In vitro pretreatment of HRBECs with BPA essentially
replicates the continuous environmental exposure underlying positive
urine tests in the general population. The failure of rapamycin to
induce apoptosis after BPA treatment raises concern that activation
of mTOR by continuous XE exposure could limit the effectiveness of
this drug and its analogs that are being tested in clinical trials (49,50).
Thus, a single estrogen mimic undermines multiple cell control mech-
anisms, as demonstrated here for tamoxifen and rapamycin and by
others for the chemotherapeutic agents, doxorubicin and cisplatin
(12).
Evasion of apoptosis and increased S-phase, induced by test XEs in
HRBECs,areacceptedhallmarksofcancer(51)withwideapplicability
inclinicalcancermanagement.Apoptosis occursrapidly afterinitiation
of successful chemotherapy (52,53). Tamoxifen induces apoptosis
within the ﬁrst 24 h of treatment in animal models (54,55). Radiation
therapy works by triggering apoptosis (56). High S-phase is an estab-
lished indicator of poor tumor outcome (57), and maintenance of pro-
liferation in the face of therapy indicatesinadequate treatment response
(58). Moreover, a drop in the ratio of proliferating to apoptotic cells
(Cell Turnover Index) is indicative of a response to hormone-based
therapy in benign (59) and malignant breast tissue (60). Thus, the
ability of HRBECs to evade apoptosis and continue DNA replication
after XE exposure portrays the acquisition of two fundamental pheno-
types of cancer. Another fact supporting the causative role of BPA and
MP is that both evasion of apoptosis and maintenance of S-phase are
induced in a dose-dependent manner in HRBECs.
In this study, BPA and MP exposures also led to reduced ROS in live
HRBECs.This is consistentwiththe ﬁnding thatinhibitionof the AKT/
mTOR complex correlates with a marked increase in ROS production
(61), and conversely, induction of the S6 kinase promotes resistance to
oxygen and glucose deprivation and reduction of ROS levels (62).
Being certain of the effects of free radicals is complicated because,
depending onthe levelofROS, cellular oxidative stresspromotes either
apoptosis or DNA damage (63,64). Low levels of ROS that accumulate
during normal metabolism cause repairable DNA damage, whereas
high levels of ROS are necessary for induction of apoptosis by hormone
therapy (65), chemotherapy (66) and ionizing radiation (67).
Expansion of clinical samples with limited cellularity undoubtedly
requiresadditionaleffortcomparedwiththe convenienceofinﬁnitecell
yields from immortalized lines. However, renewable samples, such as
HRBECsobtainedby RPFNA,arereadily availableand representa sig-
niﬁcantly wider population than rare immortalized human cell lines.
Eveninjustthisstudy,ifconﬁnedtocelllinesalone,themajorityoftest
samples would have been unavailable to reveal the consistent XE ef-
fects that occurred despite variable baseline levels of proteins such as
PTEN, AKT and 4EBP1 (Figure 2B). HRBECs are uniquely suited to
capture and ultimately to investigate the basis of this variability among
humans. We conclude: (i) testing ‘renewable’ samples from the at-risk
population allows a wider sampling of different genetics, hormonal
history, etc. than occur in a limited class of experimental models, (ii)
employing HRBECs in experimental studies facilitates hypothesis gen-
eration and conﬁrmation in independent sample sets (as we have done)
and (iii) the complexity of xenoestrogenic effects requires evaluation of
multiple cellular end points at this time for impact assessment instead
of relying on a single receptor or functional assay.
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